Full video transcriptClick to expand
Auto-generated transcript of @charitykface's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00This is so funny. I am not that mean.
- 0:04Let me give you a quick little rundown about me.
- 0:08So I'm five two. My starting weight was 222 pounds.
- 0:17I weigh 137 pounds now.
- 0:22I started Chazapatide in August of 2023.
- 0:29Never on name brand.
- 0:34I took the compounded version up until November-ish or December-ish, November-
- 0:43November of 2023.
- 0:47And then I started getting it from my Chinese spy.
- 0:53I've been rocking with it from China ever since.
- 1:01I let me think. What else can I tell you?
- 1:08I guess I can put up a four picture. This is me before.
- 1:12And then this is me now. I work out. I'm a Pilates princess.
- 1:20For sure, I go to Pilates two to three times a week.
- 1:24I mostly do a classical Pilates girly, but on Fridays I do take a modern Pilates
- 1:34class just to switch things up. Once a week I do work out with a trainer.
- 1:42She makes me lift weights and all that other gym, not bun stuff.
- 1:51Yeah. Oh, and I'm a night nurse. So I have a horrible sleeping schedule.
- 1:56I'm a specifically a pediatric ICU nurse.
- 2:01So there's that. And I've been a nurse for 17 years.
- 2:08Well, this year we'll make it 17 years.
- 2:12Yeah, I don't know if there's anything else you want to know, but I am not that mean.
- 2:18I do be flaming people, but I am not that mean.
GLP-1 side effects on TikTok: what the science says
Quick answer
The creator describes using tirzepatide, a dual GIP/GLP-1 receptor agonist, for over a year with a reported weight loss of approximately 85 pounds from a starting BMI of roughly 40.6, which falls in the class III obesity range. She combines the medication with structured Pilates and resistance training, a protocol consistent with clinical guidance for preserving lean mass during GLP-1-assisted weight loss. Her disclosure of sourcing tirzepatide from an unverified supplier in China raises significant safety concerns around product purity, sterility, and accurate concentration that cannot be resolved without third-party lab testing.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 side effects on TikTok: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 side effects on TikTok: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 side effects on TikTok: what the science says" from charitykface. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes using tirzepatide, a dual GIP/GLP-1 receptor agonist, for over a year with a reported weight loss of approximately 85 pounds from a starting BMI of roughly 40.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to j o r e y hope that helpsss any other qs lmk." In this clip, the useful excerpt is: "This is so funny." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator describes using tirzepatide, a dual GIP/GLP-1 receptor agonist, for over a year with a reported weight loss of approximately 85 pounds from a starting BMI of roughly 40.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes using tirzepatide, a dual GIP/GLP-1 receptor agonist, for over a year with a reported weight loss of approximately 85 pounds from a starting BMI of roughly 40.6, which falls in the class III obesity range. She combines the medication with structured Pilates and resistance training, a protocol consistent with clinical guidance for preserving lean mass during GLP-1-assisted weight loss. Her disclosure of sourcing tirzepatide from an unverified supplier in China raises significant safety concerns around product purity, sterility, and accurate concentration that cannot be resolved without third-party lab testing.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 22.5% body weight loss with tirzepatide at 72 weeks; the creator's reported 38% loss is above trial averages but not impossible with extended use and consistent exercise.
- Sourcing injectable peptides from unverified suppliers outside the US pharmaceutical supply chain carries real risks including contamination, inaccurate dosing, and lack of sterility assurance, regardless of the user's healthcare background.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 22.5% body weight loss with tirzepatide at 72 weeks; the creator's reported 38% loss is above trial averages but not impossible with extended use and consistent exercise.
- Sourcing injectable peptides from unverified suppliers outside the US pharmaceutical supply chain carries real risks including contamination, inaccurate dosing, and lack of sterility assurance, regardless of the user's healthcare background.
- Compounded tirzepatide from a regulated 503A or 503B pharmacy is not the same product as gray-market imports, and neither is equivalent to FDA-approved Mounjaro or Zepbound.
- Resistance training alongside GLP-1 receptor agonist therapy is evidence-backed: Johansson et al. (2022, Obesity Reviews) found it preserves lean mass that medication-only users tend to lose.
- Night shift work and circadian disruption are clinically relevant factors in weight loss outcomes; Tan et al. (2022, Obesity) linked poor sleep quality to reduced response to GLP-1-based therapies.
- Anyone pursuing tirzepatide for weight management should do so through a licensed provider who can prescribe a regulated product and monitor for side effects, not through gray-market supply chains.
- The creator's results are her own and reflect a combination of medication, structured exercise, and over a year of consistency. Attributing the outcome to the drug alone, or assuming the same sourcing is safe, would be a mistake.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @charitykface actually say?
The creator, a self-described pediatric ICU nurse of nearly 17 years, shared her personal weight loss journey on tirzepatide. She says she went from 222 pounds to 137 pounds at 5'2", starting in August 2023. She used compounded tirzepatide initially, then switched to sourcing it "from China." She also credits Pilates two to three times a week, weekly weight training with a trainer, and acknowledges working night shifts with a disrupted sleep schedule.
The video is a reply to a follower question, essentially a personal background reel. She is not explicitly giving medical advice, but her sourcing disclosure, specifically buying tirzepatide from an unregulated Chinese supplier, is the detail that matters most here and it is a serious one.
Does the science back this up?
The weight loss results she describes are plausible and consistent with published trial data. Tirzepatide (the active ingredient in Mounjaro and Zepbound) has shown strong efficacy in clinical trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found participants lost up to 22.5% of body weight over 72 weeks at the highest dose. For someone starting at 222 pounds, reaching 137 pounds, a loss of roughly 85 pounds or about 38%, would be on the high end of outcomes, though not impossible, especially combined with consistent exercise over more than a year.
Her exercise routine, Pilates plus resistance training, also lines up with evidence. A 2022 meta-analysis (Johansson et al., Obesity Reviews) found that combining GLP-1 receptor agonist therapy with structured exercise preserved lean muscle mass better than medication alone. That matters because tirzepatide users can lose significant muscle alongside fat if they are not actively resistance training.
What did they get wrong (or right)?
She got the exercise piece right, and her results, while impressive, are within the range of what the drug can do when combined with lifestyle changes.
What she got wrong, and this needs to be said plainly, is the sourcing. Saying "I've been rocking with it from China ever since" is not a quirky flex. Peptides sourced from unverified Chinese suppliers are not pharmaceutical-grade products. They are not subject to FDA oversight, USP standards, or any compounding pharmacy regulations. A 2023 investigation by the Alliance for Pharmacy Compounding flagged widespread quality variance in gray-market peptide supply chains, including contamination risks and mislabeled concentrations.
She also consistently calls it "Chazapatide," which appears to be a mispronunciation of tirzepatide. Minor, but worth noting for anyone searching for what she is actually taking.
Her nurse credentials lend her credibility, but healthcare workers self-sourcing unregulated injectable peptides is genuinely risky behavior, not something to normalize with 6,000 viewers watching.
What should you actually know?
Tirzepatide is a dual GIP and GLP-1 receptor agonist with strong clinical evidence behind it. The results the creator describes are plausible. But the method she used to obtain it after November 2023 falls entirely outside regulated channels, and that distinction is not trivial.
Compounded tirzepatide from an FDA-registered 503A or 503B compounding pharmacy is a different product category from gray-market imports, and neither is equivalent to the FDA-approved brand-name drug. The risks of unregulated injectable products include unknown sterility, inaccurate dosing, and contamination. These are not theoretical concerns.
If you are considering tirzepatide for weight management, the appropriate path is through a licensed telehealth provider or physician who can evaluate your health history, prescribe an FDA-approved product or a compounded version from a regulated pharmacy, and monitor your progress. The results this creator describes are real for her. The supply chain she used to get there is not a model anyone should follow.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
charitykface · TikTok creator
6.2K views on this video
Replying to @J O R E Y Hope that helpsss. Any other Qs lmk
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) documented up to 22.5%?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 22.5% body weight loss with tirzepatide at 72 weeks; the creator's reported 38% loss is above trial averages but not impossible with extended use and consistent exercise.
What does the video say about sourcing injectable peptides from unverified suppliers outside the us pharmaceutical?
Sourcing injectable peptides from unverified suppliers outside the US pharmaceutical supply chain carries real risks including contamination, inaccurate dosing, and lack of sterility assurance, regardless of the user's healthcare background.
What does the video say about compounded tirzepatide from a regulated 503a?
Compounded tirzepatide from a regulated 503A or 503B pharmacy is not the same product as gray-market imports, and neither is equivalent to FDA-approved Mounjaro or Zepbound.
What does the video say about resistance training alongside glp-1 receptor agonist therapy?
Resistance training alongside GLP-1 receptor agonist therapy is evidence-backed: Johansson et al. (2022, Obesity Reviews) found it preserves lean mass that medication-only users tend to lose.
What does the video say about night shift work?
Night shift work and circadian disruption are clinically relevant factors in weight loss outcomes; Tan et al. (2022, Obesity) linked poor sleep quality to reduced response to GLP-1-based therapies.
What does the video say about anyone pursuing tirzepatide for weight management should do so through?
Anyone pursuing tirzepatide for weight management should do so through a licensed provider who can prescribe a regulated product and monitor for side effects, not through gray-market supply chains.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by charitykface, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.